SCHEMBL6830740

SCHEMBL6830740

COc1cccc(-c2nccc3ncccc23)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 0.55
DYRK1A Q13627 1/20 0.55
ADORA2A P29274 1/20 0.53
KCNA5 P22460 1/20 0.48
CCNB2 O95067 1/20 0.48
CDK1 P06493 1/20 0.48
CCNB1 P14635 1/20 0.48
GSK3A P49840 1/20 0.48
GSK3B P49841 1/20 0.48
CDK5 Q00535 1/20 0.48
CDK5R1 Q15078 1/20 0.48
CCNB3 Q8WWL7 1/20 0.48
SYK P43405 1/20 0.47
TOP1 P11387 1/20 0.47
MAP4K4 O95819 1/20 0.47
MAOB P27338 1/20 0.46
AURKA O14965 1/20 0.46
CYP1A2 P05177 3/20 0.45
CYP3A4 P08684 3/20 0.45
USP2 O75604 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9376993 0.82 DYRK1A (0.51) CLK4DYRK1AADORA2AKCNA5CCNB2
SCHEMBL29808138 0.81 ADORA2A (0.55) CLK4DYRK1AADORA2ACYP1A2CYP3A4
SCHEMBL1038650 0.81 ADORA2A (0.55) CLK4DYRK1AADORA2ACYP1A2CYP3A4
SCHEMBL29986853 0.81 ADORA2A (0.62) CLK4DYRK1AADORA2AMAP4K4CYP1A2
SCHEMBL28872928 0.81 ADORA2A (0.62) CLK4DYRK1AADORA2AMAP4K4CYP1A2
SCHEMBL10094648 0.78 DYRK1A (0.62) CLK4DYRK1AADORA2AKCNA5CCNB2
SCHEMBL28824499 0.78 CLK4 (0.62) CLK4DYRK1AKCNA5CCNB2CDK1
SCHEMBL16047508 0.78 KCNA5 (0.62) CLK4DYRK1AADORA2AKCNA5SYK
SCHEMBL27290306 0.78 CLK4 (0.53) CLK4DYRK1AADORA2ACCNB2CDK1
SCHEMBL18703927 0.78 MAP4K4 (0.52) CLK4DYRK1AADORA2AKCNA5SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6743803-B2 SUCH AS ALZHEIMER'S DISEASE AND SCHIZOPHRENIA DUE TO HYPOFUNCTION OF GLUTAMIC ACID RECEPTOR; 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-06-01 US disclosed